Down's sufferers may benefit from research, says Bupa

clock

Medicines that target specific nerve cells in the brain could reverse poor mental function in people with Down's syndrome, according to new research, Bupa has said.

Down’s syndrome is caused by having an extra chromosome. One effect is that people with Down’s syndrome have memory and learning problems. This delays brain development and means they find it difficult to adapt to changes in their environment. American researchers considered whether increasing the concentration of the chemical, noradrenaline, in the brains of mice bred to show similar symptoms could reverse problems with brain function. If so, this could also be effective in humans who have Down’s syndrome. The scientists found that when the mice were put into an unfamiliar cage they ...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Protection

The family tree: Protection through the generations

The family tree: Protection through the generations

Protection needs during different life stages

Gregor Sked
clock 04 December 2024 • 4 min read
Protection: Should our finances be single or joint?

Protection: Should our finances be single or joint?

Single policies typically offer greater value and more flexibility

Kevin Carr
clock 02 December 2024 • 4 min read
Record protection payouts must spur advisers on

Record protection payouts must spur advisers on

These aren't products that sell themselves

Ahmed Bawa
clock 01 November 2024 • 5 min read